2,4-Dihydro-3h-1,2,4-triazol-3-one P2X7 receptor antagonists have been reported in an Axxam SpA patent as potentially useful for the treatment of cognitive, eye, gastrointestinal, genitourinary and psychiatric disorders, chronic pain, neuropathic pain and neurodegeneration.